Literature DB >> 9042304

Multiple use of a signal transduction pathway in tumor cell invasion.

J Tímár1, E Rásó, Z S Fazakas, S Silletti, A Raz, K V Honn.   

Abstract

Recent reports have indicated that a poorly characterized signaling pathway involving 12-lipoxygenase and PKC is involved in several steps of the metastatic cascade such as tumor cell adhesion to matrix, lysosomal enzyme release and migration. We investigated here the upstream elements of this signalling pathway looking for receptors which it might be coupled to. We described tumor cell alpha IIb beta 3-like integrin and the AMF receptor, gp78, as two transmembrane receptors which utilize the 12-lipoxygenase/PKC signaling. Furthermore, we compared the in vivo expression of the signal components of the "autocrine motility cycle" (gp78, 12-LOX and PKCa-Tímár et al 1993) in human prostate carcinoma cell lines (PC3 and DU145) with different invasive potential. We report here that all three components of this cycle are overexpressed three fold in vivo in the more aggressive tumor, suggesting that this signalling pathway might regulate the invasive phenotype-at least in the studied tumor cells.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9042304

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Liver metastatic ability of human melanoma cell line is associated with losses of chromosomes 4, 9p21-pter and 10p.

Authors:  Z Adám; R Adány; A Ladányi; J Tímár; M Balázs
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

2.  Expression of receptor protein tyrosine phosphatase alpha mRNA in human prostate cancer cell lines.

Authors:  S Zelivianski; J Dean; D Madhavan; F F Lin; M F Lin
Journal:  Mol Cell Biochem       Date:  2000-05       Impact factor: 3.396

Review 3.  The arachidonate 12/15 lipoxygenases. A review of tissue expression and biologic function.

Authors:  D J Conrad
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

Review 4.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

5.  Potency of non-steroidal anti-inflammatory drugs in chemotherapy.

Authors:  Lucia Hiľovská; Rastislav Jendželovský; Peter Fedoročko
Journal:  Mol Clin Oncol       Date:  2014-10-16

6.  Tumor cell motility and metastasis : Autocrine motility factor as an example of ecto/exoenzyme cytokines.

Authors:  S Silletti; S Paku; A Raz
Journal:  Pathol Oncol Res       Date:  1997-09       Impact factor: 3.201

7.  BMD188, A novel hydroxamic acid compound, demonstrates potent anti-prostate cancer effects in vitro and in vivo by inducing apoptosis: requirements for mitochondria, reactive oxygen species, and proteases.

Authors:  D G Tang; L Li; Z Zhu; B Joshi; C R Johnson; L J Marnett; K V Honn; J D Crissman; S Krajewski; J C Reed; J Timar; A T Porter
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

Review 8.  Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms.

Authors:  A Albini
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

9.  Involvement of tumor cell integrin alpha v beta 3 in hematogenous metastasis of human melanoma cells.

Authors:  Brunhilde Felding-Habermann; Emilia Fransvea; Timothy E O'Toole; Lisa Manzuk; Barbara Faha; Mary Hensler
Journal:  Clin Exp Metastasis       Date:  2002       Impact factor: 5.150

10.  Inhibition of peroxisome proliferator-activated receptor (PPAR)-mediated keratinocyte differentiation by lipoxygenase inhibitors.

Authors:  Philippe Thuillier; Alan R Brash; James P Kehrer; Julie B Stimmel; Lisa M Leesnitzer; Peiying Yang; Robert A Newman; Susan M Fischer
Journal:  Biochem J       Date:  2002-09-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.